Alcon, the global leader in eye care and second-largest division of Novartis, announced that its treatment for patients with glaucoma, Travatan (40µg/mL travoprost) eye drops solution, has been granted an additional indication by the European Commission to decrease elevated intraocular pressure (IOP) in pediatric patients, aged two months to less than 18 years, with ocular hypertension or pediatric glaucoma. Travatan is currently indicated to decrease elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma.

Glaucoma is a progressive eye disease that damages the optic nerve, resulting in gradual, irreversible loss of vision, and eventually blindness if left untreated or not adequately managed. Elevated eye pressure, or IOP, is considered the main risk factor for glaucoma.

For more details, go to: http://www.novartis.com/newsroom/media-releases/en/2014/1882951.shtml